Table 2. Prevalence of comorbidities at baseline and after 12 and 24 months of laparoscopic sleeve gastrectomy (LSG) in severely obese adolescents.
| Measure | Baseline | 12 months | 24 months | p value |
|---|---|---|---|---|
| SAH | 13/22 (59.1%) | 3/17 (17.6%) | 3/14 (21.4%) | 0.023 |
| type 2 DM | 1/22 (4.5%) | 0/12 (0%) | 0/13 (0%) | 0.999 |
| OGI | 2/22 (9.1%) | 0/12 (0%) | 0/13 (0%) | 0.999 |
| LV hypertrophy | 3/22 (13,6%) | 0/12 (0%) | 0/12 (0%) | 0,999 |
| HOMA-IR > 2.5 | 21/22 (95.5%) | 4/12 (33.3%) | 6/13 (46.2%) | 0.046 |
| Hepatic steatosis | 12/22 (54.5%) | 2/12 (16.7%) | 1/14 (7.1%) | 0.027 |
| Dyslipidemia | 21/22 (95.5%) | 2/12 (16.7%) | 3/13 (23.1%) | 0.004 |
| Metabolic syndrome | 4/22 (18.2%) | 4/22 (18.2%) | 1/14 (7.1%) | 0.479 |
SAH: systemic arterial hypertension; type 2 DM: type 2 diabetes; OGI: oral glucose intolerance; LV hypertrophy: left ventricular hypertrophy; HOMA-IR: homeostatic model assessment of insulin resistance.